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Detailed knowledge of the pathways bywhich ghrelin
and leptin signal to AMPK in hypothalamic neurons
and lead to regulation of appetite and glucose ho-
meostasis is central to the development of effective
means to combat obesity. Here we identify CaMKK2
as a component of one of these pathways, show that
it regulates hypothalamic production of the orexi-
genic hormone NPY, provide evidence that it func-
tions as an AMPKa kinase in the hypothalamus,
and demonstrate that it forms a unique signaling
complex with AMPKa and b. Acute pharmacologic
inhibition of CaMKK2 in wild-type mice, but not
CaMKK2 null mice, inhibits appetite and promotes
weight loss consistent with decreased NPY and
AgRP mRNAs. Moreover, the loss of CaMKK2 pro-
tects mice from high-fat diet-induced obesity, insulin
resistance, and glucose intolerance. These data
underscore the potential of targeting CaMKK2 as
a therapeutic intervention.
INTRODUCTION
Obesity and associated diseases such as type 2 diabetes, hy-
pertension, cardiovascular disorders, and some cancers are
a threat to general human health and have stimulated increased
interest in understanding the molecular mechanisms responsible
for coordinated food intake, body weight, and glucose homeo-
stasis (Zamboni et al., 2005). Recent findings have emphasized
the role of the central nervous system (CNS), especially the hy-
pothalamus, in integrating hormonal and nutrient signals from
the periphery to modulate food intake, energy expenditure,
and peripheral glucose metabolism (Morton et al., 2006). For ex-
ample, abundant evidence indicates that the CNS is the site for
the appetite-controlling actions of leptin. Much progress has
been made in identifying neuronal populations in the arcuate
nucleus (ARC) and ventromedial hypothalamus (VMH) of the
hypothalamus that are directly responsive to leptin; the signalingsteps leading to transcriptional activation upon engagement of
the leptin receptor; and the neuronal circuitry linking leptin-
responsive neurons with populations of neurons that underlie
leptin’s endocrine, autonomic, and behavioral effects (Elmquist
et al., 2005; Flier, 2004; Friedman and Halaas, 1998). Unfortu-
nately, while administration of leptin causes weight loss in lean
mammals, there is typically leptin resistance in obese individuals
that compromises the use of leptin to treat obesity (Heymsfield
et al., 1999).
An emerging view holds that common neuronal circuitry is
used by a variety of hormones and metabolites that affect energy
homeostasis. One especially important example is ghrelin, which
is produced by the stomach and opposes the hypothalamic ac-
tions of leptin by stimulating food intake. Plasma ghrelin levels
display an episodic secretory pattern, rising shortly before meals
and falling sharply on feeding (Bagnasco et al., 2002). Ghrelin
also rises with acute fasting or chronic food deprivation and in re-
sponse to weight loss due to chronic exercise, eating disorders,
and cancer anorexia. Notably, the same effect occurs following
diet-induced weight loss, suggesting a mechanism for the re-
bound weight gain following dieting (Cummings et al., 2002). It
is through the upregulation of NPY and AgRP, the most potent
physiological appetite transducers known in mammals, that
ghrelin mediates its effect on food intake (Kalra and Kalra,
2004). Ghrelin binds the Gq-coupled growth hormone secreta-
gogue receptor expressed on NPY neurons in the ARC, which
leads to the increase in intracellular Ca2+ required for transcrip-
tional activation of the NPY and AgRP genes (Holst et al.,
2005; Kohno et al., 2003; Kojima et al., 1999; Sun et al., 2004).
Administration of NPY to rodents rapidly causes voracious feed-
ing and leads to increased adiposity over prolonged periods
(Clark et al., 1984). Blocking NPY action or selectively ablating
NPY neurons in rodents suppresses feeding and reduces obe-
sity and fasting-induced responses (Broberger and Hokfelt,
2001; Gropp et al., 2005; Luquet et al., 2005). In some situations,
inhibition of NPY signaling reduces food intake and body weight
without cachexia or rebound weight gain (Lambert et al., 2001).
These observations have prompted efforts to design antagonists
to NPY and to NPY receptors as therapeutics. However, poor
bioavailability and brain penetration and nonselective nature of
action have thus far confounded development of an effectiveCell Metabolism 7, 377–388, May 2008 ª2008 Elsevier Inc. 377
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signaling components in the pathway (Kalra and Kalra, 2004).
Recently, the AMP-dependent protein kinase (AMPK) was
identified as one such signaling component. The intraperitoneal
(i.p.) or intracerebroventricular (i.c.v.) injection of ghrelin in
rodents increases the phosphorylation and activation of AMPK
in the hypothalamus, while i.c.v. administration of a pharmaco-
logical AMPK activator (AICAR) stimulates food intake and
body weight gain in these animals (Andersson et al., 2004;
Kola et al., 2005). In addition, analysis of dissected hypothalami
has demonstrated a correlation between altered levels of AMPK
activity and expression of NPY (Minokoshi et al., 2004). Collec-
tively, the data indicate a role for AMPK in NPY neurons, down-
stream of ghrelin and upstream of NPY gene expression and the
stimulation of appetite.
The AMPK holoenzyme is a heterotrimer comprised of a cata-
lytic and b and g regulatory subunits and requires phosphoryla-
tion of the a subunit on Thr172 by an upstream activating kinase
for activity (Hardie et al., 2003). Numerous studies indicate that
the tumor suppressor protein LKB1, mutations of which lead to
Peutz-Jeghers syndrome, is the relevant AMPK kinase (AMPKK)
when AMPK is responding to acute changes in energy balance
that occur at the cellular level (Sakamoto et al., 2005; Shaw
et al., 2004, 2005). In this context, AMPK activation also requires
50-AMP, which binds the g regulatory subunit and allosterically
activates the kinase, while at the same time inhibiting dephos-
phorylation of Thr172 by PP2C. Thus, an increase in the AMP/
ATP ratio that occurs when ATP levels are depleted is sensed
by AMPK. Once activated, AMPK switches off anabolic path-
ways and other processes that consume ATP, such as lipid
and carbohydrate synthesis, while switching on catabolic path-
ways that generate ATP, such as fatty acid oxidation and glu-
cose uptake, in order to restore energy balance. The AMP/
LKB1-dependent activation of AMPK results from pathological
stresses such as heat shock, hypoxia, and glucose deprivation
and is responsible for mediating activation of AMPK by the
antidiabetic drug metformin. Physiological stimuli such as con-
traction-stimulated glucose uptake by muscle cells and glucose
homeostasis in liver also depend on this pathway. Thus, in
peripheral tissues, it is desirable to activate AMPK.
Recently, the Ca2+/calmodulin (CaM)-dependent protein
kinase kinases (CaMKK) were shown to function as physiologi-
cally relevant AMPK kinases in cells, observations that have
broadened the scope of AMPK regulation (Hawley et al., 2005;
Hurley et al., 2005; Woods et al., 2005). In contrast to that
directed by AMP/LKB1, the CaMKK-dependent activation of
AMPK operates independently of AMP, instead requiring
a change in intracellular Ca2+. The abundant expression of
CaMKK in brain led us to predict that Ca2+/CaM/CaMKK may
regulate the phosphorylation of AMPK in NPY neurons of the hy-
pothalamus and that, if so, it would be desirable to inactivate
AMPK in this tissue (Witters et al., 2006).
Here we show that primary defects in mice null for CaMKK2
are reduced hypothalamic AMPK activity and downregulation
of NPY and AgRP gene expression in NPY neurons. Acute
i.c.v. administration of a CaMKK antagonist to wild-type mice,
but not CaMKK2 null mice, results in decreased food intake
that correlates with decreased hypothalamic NPY and AgRP
mRNAs. Intriguingly, the absence of CaMKK2 also protects378 Cell Metabolism 7, 377–388, May 2008 ª2008 Elsevier Inc.mice from diet-induced weight gain, hyperglycemia, and insulin
resistance, and we infer that the mechanism involved may also
involve hypothalamic AMPK. Finally, we identify and character-
ize a unique complex comprised of CaMKK2, AMPKa/b, and
Ca2+/CaM that may be the physiologically relevant signaling
complex for mediating these central effects on energy
homeostasis.
RESULTS
CaMKK2 Regulates NPY in the Hypothalamus
CaMKK2 is expressed throughout the brain, although its pres-
ence in hypothalamus has not been specifically examined
(Anderson et al., 1998). Immunoblotting of hypothalamic extracts
from wild-type (WT) mice revealed that CaMKK2 protein is pres-
ent in this part of the brain (Figure 1A) and appears as a doublet,
consistent with findings in HeLa cells (Hurley et al., 2005). The
hypothalamus is divided into regions including the ARC, VMH,
and lateral hypothalamus (LH), each with unique functions and
all previously shown to express AMPK. To identify regions where
CaMKK2 might colocalize with AMPK and function as an
AMPKK, its expression pattern in the hypothalamus was exam-
ined by in situ hybridization. Coronal sections of adult mouse
brain were collected from the midregion of the hypothalamus
and incubated with antisense riboprobes designed to hybridize
with MCH, NPY, or CaMKK2 mRNAs. NPY and MCH are neuro-
peptides expressed within neurons present only in the ARC or
VMH, respectively, and served as positive controls. Consistent
with previous studies in rat brain, CaMKK2 signal was strong in
the hippocampus and cortex and was shown here to be present
in the hypothalamus, where it appeared largely restricted to the
ARC (Figure 1B). Compared to NPY, CaMKK2 expression is
observed throughout a larger region, suggesting its presence
in multiple cell types. When mRNA levels were quantified from
ARC punches, CaMKK2, NPY, AgRP, and POMC were found
to be enriched 20- to 40-fold relative to whole hypothalamus
(Figure 1C). In contrast, MCH was barely detectable. Hypotha-
lamic punches that failed to display enrichment for NPY showed
correspondingly reduced levels of CaMKK2 (data not shown).
This finding, together with the in situ hybridization result, is con-
sistent with localization of CaMKK2 to NPY and POMC neurons
present in the ARC; however, it cannot provide unequivocal
assignment of CaMKK2 to specific neuron types. To evaluate
the possibility of a functional correlation between CaMKK2 and
NPY, we compared hypothalamic NPY, AgRP, and POMC
mRNA levels in WT and CaMKK2 null mice. Figure 1D shows
decreasedNPY and AgRP levels in the mutant, but no significant
difference in POMC. These results implicate CaMKK2 in a
pathway that regulates NPY and AgRP in NPY neurons.
Since CaMKK2 can function as an AMPK in cells, we ques-
tioned whether the absence of CaMKK2 alters hypothalamic
AMPK activity. AMPK was immunoprecipitated from protein
extracts prepared from WT and CaMKK2 null mice and assayed
in vitro. A statistically significant decrease in AMPK activity was
observed in the CaMKK2 null samples (Figure 1E), consistent
with diminished AMPK-NPY signaling. We suspect that the mod-
est decrease in total hypothalamic AMPK activity reflects the
observation that CaMKK2 expression is restricted to a small
region of the hypothalamus and is considerably enriched in
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AMPK activity is detected throughout the hypothalamus
(Minokoshi et al., 2004).
Ghrelin stimulates food intake via binding to growth hormone
secretagogue receptors (GHS-Rs) present on NPY neurons,
which leads to an increase in intracellular Ca2+ and activation
of the AMPK-NPY pathway (Cummings et al., 2005). This signal-
ing pathway was further evaluated by systemic administration of
ghrelin to WT and CaMKK2 null mice. Ghrelin increased food
intake of WT animals at 1 hr and overnight but had no effect on
food intake of CaMKK2 null mice (Figure 1F). The ghrelin signal
can be bypassed by 2-deoxyglucose (2-DG), which causes
AMP/LKB1-dependent activation of AMPK due to depletion of
cellular energy stores, which raises the AMP/ATP ratio. As
shown in Figure 1G, systemic administration of 2-DG stimulated
the food intake of both WT and CaMKK2 null mice to the same
extent. Collectively, our data are consistent with a signaling de-
fect in the NPY neurons of CaMKK2 null mice lying downstream
of ghrelin and upstream of AMPK that affects the expression of
NPY and AgRP mRNAs.
STO-609 Blocks Ca2+-Dependent Induction of NPY
As we wanted to provide more direct evidence linking CaMKK2,
AMPK, and NPY production, we turned to N38 cells, an immor-
talized cell line derived from mouse hypothalamus that have
been shown to express NPY. These cells express CaMKK2
(Figure 2A) and other components of the AMPK signaling path-
way that can be activated by treating the cells with exogenous
stimuli. Ionomycin, which increases intracellular Ca2+ leading
to activation of CaMKK2, and 2-DG, which raises the AMP/
ATP ratio by inhibiting cellular production of ATP, both result in
increased levels of phosphorylated AMPK (p-AMPK) and
Figure 1. CaMKK2 Is Expressed in the
Hypothalamus and Regulates NPY
(A) CaMKK2 protein is expressed in the hypothal-
amus. Protein extracts of hypothalamus from
wild-type (WT) and CaMKK2 null (KO) mice were
immunoblotted for CaMKK2. CaMKK2 protein
appears as a doublet in the WT sample and is
absent from the KO sample.
(B) CaMKK2 mRNA is expressed in the hypothala-
mus. Coronal mouse brain sections collected at
the midregion of the hypothalamus were incu-
bated as indicated with antisense riboprobes
against NPY and MCH, which serve as positive
controls for the arcuate nucleus (ARC) and ventro-
medial hypothalamus (VMH), respectively, and
against CaMKK2.
(C) CaMKK2, NPY, AgRP, and POMC mRNAs are
enriched in ARC punch biopsies from hypothala-
mus of WT mice. n = 3.
(D) NPY and AgRP mRNA levels are decreased in
hypothalamus of CaMKK2 null mice. Total RNA
was isolated from hypothalamus of WT and
CaMKK2 null mice that had been fasted overnight,
and NPY, AgRP, and POMC mRNA levels were
quantified by RT-PCR. n = 8; *p < 0.05.
(E) AMPK activity is decreased in hypothalamus of
CaMKK2 null mice. Following immunoprecipita-
tion of AMPK from hypothalamic extracts of fasted
WT and CaMKK2 null mice, AMPK activity was
determined in vitro with SAMS peptide as
substrate. A representative experiment is shown.
n = 4; *p < 0.05.
(F) Food intake of CaMKK2 null mice is unaffected
by exogenously administered ghrelin. WT and
CaMKK2 null mice were given intraperitoneal
(i.p.) injections of saline or ghrelin (3 nmol/100 ml
per mouse) 1 hr before onset of dark cycle, and
food intake was quantified at 1 hr and overnight.
n = 11 (WT), n = 12 (CaMKK2 null); *p < 0.05.
(G) Food intake of CaMKK2 null and WT mice is
affected similarly by 2-DG. In the control experi-
ment, mice were given i.p. injections of 2-deoxy-
glucose (2-DG) at a dose of 15 mg/100 ml per
mouse, and food intake was monitored as in (F).
n = 11 (WT), n = 12 (CaMKK2 null); *p < 0.05.
Data are presented as means ± SEM.Cell Metabolism 7, 377–388, May 2008 ª2008 Elsevier Inc. 379
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blocks the ionomycin-induced increases in p-AMPK and
p-ACC, but not the phosphorylation of these proteins in re-
sponse to 2-DG (Figure 2B). We used immunocytochemistry to
show that ionomycin increases the amount of NPY in N38 cells
and that this increase is prevented by the selective CaMKK inhib-
itor STO-609 (Tokumitsu et al., 2002) (Figures 2C and 2D). These
data support our contention that a rise in Ca2+ results in activa-
tion of CaMKK2, which in turn phosphorylates AMPK, leading to
an increase in NPY.
Depletion or Inhibition of CaMKK2 Inhibits Food Intake
NPY is a well-established potent orexigenic factor, and depleting
NPY signaling in mice reduces refeeding after a fast. This pheno-
type is most severe during the first hour of the refeeding period
and gradually returns to normal by 24 hr (Segal-Lieberman
et al., 2003). When refeeding behavior was examined inCaMKK2
Figure 2. Ca2+-Dependent Induction of NPY
Expression in N38 Cells Is Blocked by
STO-609
(A) CaMKK2 protein is detected in N38 cell protein
extracts by immunoblotting.
(B) N38 cells were incubated for 1 hr with vehicle or
with 10 mM STO-609, followed by stimulation with
1 mM ionomycin for 5 min or 50 mM 2-DG for
15 min. Cell extracts were prepared and immuno-
blotted for phosphorylated AMPK (p-AMPK), total
AMPK, and p-ACC. STO-609 selectively blocks
the ionomycin-induced increase in p-AMPK and
p-ACC. One representative experiment is shown.
(C) N38 cells were incubated for 1 hr with vehicle or
with 10 mM STO-609, followed by stimulation with
1 mM ionomycin or with 50 mM 2-deoxy glucose
(2-DG) for 6 hr. The cells were then fixed, and the
NPY protein signal (red) was visualized by immu-
nocytochemistry. The cells were costained with
the DAPI nuclear marker (blue). One representa-
tive experiment is shown. n = 3.
(D) NPY signal intensity in (C) was quantified using
MetaMorph version 7.1 software. Forty cells were
analyzed for each condition. Shown are means ±
SEM. n = 40; *p < 0.0002.
null animals, they were found to exhibit
a defect similar to that previously reported
for NPY-depleted mice (Figure 3A). After
a 48 hr fast, CaMKK2 null mice ate less
than WT mice during a 6 hr refeeding pe-
riod, with the greatest decrease in food in-
take occurring at the early time points, but
by 48 hr the difference was abrogated
(Figure 3A). Figure 3B shows the food in-
take of nonfasted wild-type and CaMKK2
null control animals over a 48 hr period.
Intracerebroventricular administration
of NPY to rats leads to robust induction
of food intake, while chronic infusion
results in increased adiposity and insulin
resistance (Clark et al., 1984), and abla-
tion of NPY neurons in adult mice induces life-threatening an-
orexia (Gropp et al., 2005; Luquet et al., 2005). The hypothesis
that CaMKK2 controls appetite by regulating NPY gene expres-
sion in the hypothalamus predicts that acute inhibition of
CaMKK2 in adult WT animals should decrease appetite. To
test this idea, the selective CaMKK inhibitor STO-609 (Tokumitsu
et al., 2002) was administered i.c.v. to adult male WT mice, and
the effect on appetite was assessed by quantifying food intake.
Compared to animals receiving saline, the WT STO-609 group
ate significantly less food during the 6 days over which food in-
take was monitored (Figure 3C) and also lost body weight
(Figure 3E). We repeated the food intake experiment using adult
male CaMKK2 null mice. Whereas the CaMKK2 mice receiving
vehicle consumed food to the same extent as similarly treated
WT mice, STO-609 did not alter the feeding behavior or decrease
the body weight of CaMKK2 null mice (Figures 3D and 3F). As
predicted, the WT animals receiving STO-609 also exhibited
decreased hypothalamic NPY and AgRP mRNAs compared to380 Cell Metabolism 7, 377–388, May 2008 ª2008 Elsevier Inc.
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NPY and AgRP mRNA expression in WT mice, but not CaMKK2
null mice, provide compelling independent evidence that
CaMKK2 signaling is required for appetite control.
CaMKK2/ Mice Are Resistant to a High-Fat Diet
Diminished NPY signaling in CaMKK2/ mice suggests that
these animals will eat less due to decreased appetite and accu-
mulate less body weight over time. To test this idea, we utilized
the Surwit diet, a calorie-paired low-fat/high-fat diet that is com-
monly referred to as the diet-induced obese model and that was
developed for C57BL/6J mice, the predominant genetic back-
ground of our mice (Petro et al., 2004; Surwit et al., 1988). For
this experiment, WT and CaMKK2/ mice were fed either
a low-fat control diet (D12328 CCO) or the high-fat equivalent of
this diet (D12330 HCO) from weaning (3 weeks of age) to 34 weeks
of age. As shown in Figure 4, the body weight gain ofCaMKK2/
mice as monitored during the 31 weeks was significantly
Figure 3. Depletion or Inhibition of CaMKK2
Inhibits Food Intake
(A) CaMKK2 null mice display reduced refeeding
after a fast. Food intake was quantified hourly dur-
ing a 6 hr refeeding period and at 48 hr, following
a 48 hr fast. n = 7; *p < 0.02.
(B) In the control experiment, the food intake of
nonfasted animals was measured.
(C and D) Intracerebroventricular (i.c.v.) adminis-
tration of STO-609 to WT mice, but not toCaMKK2
null mice, decreases food intake. STO-609 was
administered i.c.v. to WT and CaMKK2 null mice
continuously for 6 days at a concentration of
20 mM and a rate of 0.5 ml/hr, during which time
food intake was measured daily. Cumulative
food intake is shown. n = 9; *p < 0.05 (C); n = 10 (D).
(E and F) Change in body weight by the end of the
6 day experiment is plotted as a percentage of
the starting value obtained before the cannulation
surgery. n = 7.
(G) At the end of the experiment, WT animals were
sacrificed, and hypothalamic NPY and AgRP
mRNAs were quantified by real-time PCR. n = 7;
*p < 0.05.
Data are presented as means ± SEM.
decreased compared to WT controls for
animals fed low-fat chow (Figure 4A), and
this difference was enhanced for animals
maintained on high-fat chow (Figure 4B).
Consistent with the observed reduction
in body weight, CaMKK2 null mice
displayed a reduced average daily food in-
take over the course of the experimentand
a reduction in adiposity measured after 31
weeks on either diet (Figures 4C and 4D).
After 31 weeks on the two diets, the abil-
ity of the animals to handle glucose was
evaluated. Glucose tolerance testing re-
vealed that WT mice on the high-fat diet
had become less tolerant compared with
WT animals maintained on low-fat chow
(Figures 4E and 4F). The observed increase in glucose excursion
exhibited by WT mice fed high-fat chow is typical of that previ-
ously attributed to a diet-induced change (Petro et al., 2004; Sur-
wit et al., 1988). CaMKK2/ mice on low-fat chow responded
to glucose similarly to WT mice on low-fat chow. However, unlike
WT animals, the CaMKK2/ mice retained the low-fat-diet-like
response to glucose even when fed high-fat chow for 31 weeks
(Figures 4E and 4F). After 1 week of recovery, the same group of
animals was tested for insulin sensitivity. Consistent with the re-
sults from the glucose tolerance testing, WT mice had developed
the predicted increase in insulin resistance, whereasCaMKK2null
animals were protected from diet-induced changes in insulin
action (Figures 4G and 4H).
After an additional several weeks of recovery, the animals were
sacrificed and serum levels of ghrelin and leptin were quantified.
As shown in Figure 4I, CaMKK2/ animals did not exhibit a de-
crease in ghrelin levels, indicating their ability to synthesize and
secrete ghrelin. In fact, ghrelin levels were increased in CaMKK2Cell Metabolism 7, 377–388, May 2008 ª2008 Elsevier Inc. 381
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compensate for a defect in the ghrelin signaling pathway by in-
creasing its production. Consistent with this idea, serum leptin
was decreased inCaMKK2 null mice (Figure 4J). This also follows
from the defect in the ghrelin pathway, as the NPY neurons would
respond to a decrease in ghrelin activity as if there had been an
increase in leptin. Indeed, hypothalamic NPY mRNA was de-
creased in the CaMKK2 null mice fed the high-fat diet relative
to WT mice, and the decrease was accentuated upon fasting
(Figure 4K). Together, these data are consistent with our observa-
tions in Figure 1 thatCaMKK2 null mice cannot respond to ghrelin
with the appropriate increase in feeding and body weight gain
and that this may be due in part to decreased production of NPY.
CaMKK2 and AMPK Form a Signaling Complex
A central tenet of signal transduction is that the appropriate
propagation of signals along a pathway often depends on forma-
Figure 4. CaMKK2 Null Mice Consume
Less Food and Are Resistant to High-Fat
Diet-Induced Adiposity, Glucose Intoler-
ance, and Insulin Resistance
Twenty male WT and CaMKK2 null mice were
housed five per cage at the age of weaning and
fed control (D12328) or high-fat (D12330) diets
from Research Diets for 31 weeks. Measurements
of food intake and weight gain were performed
weekly.
(A and B) Growth curves of the two groups on both
diets show that the CaMKK2 null mice gain signif-
icantly less weight than the WT mice. *p < 0.01 by
one-way ANOVA.
(C) Average daily food intake of CaMKK2 null mice
is reduced compared to control animals. *p < 0.02.
(D) Dual energy X-ray absorptiometry (DEXA) scans
of CaMKK2 null mice indicate a significant de-
crease in adiposity compared to WT animals after
31weekson either control or high-fatdiet. *p < 0.02.
(E–H) On the high-fat diet, CaMKK2 null mice also
remain glucose tolerant (E and F) and insulin sensi-
tive (G and H) relative to WT mice. *p < 0.01.
(I and J) After 31 weeks on low-fat (n = 5) or high-fat
(n = 10) diet, WT and CaMKK2 null mice were sac-
rificed,and total serum ghrelin (I) and leptin (J) levels
were quantified. *p < 0.05.
(K) After 31 weeks on high-fat chow, WT and
CaMKK2 null mice were either fasted overnight or
fed ad libitum. The animals were then sacrificed,
and hypothalamic NPY mRNA levels were quanti-
fied by real-time PCR. n = 4; *p < 0.02.
Data are presented as means ± SEM.
tion of a complex of its components. To
determine whether CaMKK2 associates
with AMPK, the AMPKa subunit was im-
munoprecipitated from mouse brain ex-
tract and probed for CaMKK2. CaMKK2
does coprecipitate with AMPKa from
mouse brain (Figure 5A). The interaction
was further characterized using a FLAG-
tagged version of CaMKK2 overex-
pressed in HEK293A cells, which represents a convenient
cell-based system. The transfected FLAG-CaMKK2 appears to
be functionally linked to AMPK, as both basal and ionomycin-
induced phosphorylation of AMPK were increased by the pres-
ence of the kinase (Figure 5B). Moreover, endogenous AMPK
and FLAG-CaMKK2 associate in HEK293A cells, as p-AMPK
coimmunoprecipitated with FLAG-CaMKK2 (Figure 5C). Also
detected in the FLAG-CaMKK2 immunoprecipitate was
p-ACC, a downstream target of activated AMPK, and CaM,
which is required for CaMKK2 activity. The association between
CaMKK2, AMPK, ACC, and CaM disappeared when the metal
chelators EDTA and EGTA were included during cell lysis and
immunoprecipitation, although the chelators had no effect on
the ability to precipitate CaMKK2 (Figure 5C), suggesting that
Ca2+/CaM and/or MgATP are required for complex formation.
AMPK is believed to exist in cells predominantly as a hetero-
trimer composed of the a catalytic and the b and g regulatory
subunits, which function to stabilize, localize, and confer AMP382 Cell Metabolism 7, 377–388, May 2008 ª2008 Elsevier Inc.
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which has been found to physically associate with LKB1. To
determine the subunit composition of the AMPK present in the
CaMKK2 complex, FLAG-CaMKK2 was immunoprecipitated
from HEK293A cells and probed for the different subunits.
Both isoforms of the AMPK catalytic subunit (a1 and a2) were
identified in the absence, but not the presence, of metal chela-
tors (Figure 5D), as were the b1/2 subunits (Figure 5E). However,
the g subunits were not detected, an observation confirmed us-
ing several g subunit antibodies (Figure 5E and data not shown).
In a related experiment, FLAG-CaMKK2 immunoprecipitated
from HEK293A cells was compared with purified trimeric
AMPK (Figure 5F) determined by Coomassie staining to be
composed of stoichiometric amounts of a, b, and g (data not
shown). Although AMPKa and b were present in the CaMKK2
complex at levels similar to those observed in purified trimeric
AMPK, once again g was not detected. These results reveal
that CaMKK2 may form a stable complex containing a catalytic
and b structural subunits of AMPK but not the g regulatory
subunits.
The CaMKK RP domain, a 23-residue arginine/proline-rich
insert between subdomains II and III of the kinase homology do-
main, has been previously shown to function as a protein-protein
interaction domain in CaMKK1 (Tokumitsu et al., 1999). Deletion
of this region from CaMKK2 produced a mutant protein that was
unable to interact with AMPK in the coimmunoprecipitation
Figure 5. CaMKK2 Forms a Signaling
Complex with AMPK
(A) CaMKK2 coimmunoprecipitates with AMPK
from mouse brain. Brain extracts were incubated
with AMPKa antibody (lanes 1 and 3) or preim-
mune serum (lanes 2 and 4). The immunoprecipi-
tates were then immunoblotted for CaMKK2.
(B) FLAG-CaMKK2 increases basal and ionomy-
cin-induced phosphorylation of AMPK. HEK293A
cells transfected with FLAG-CaMKK2 or with con-
trol plasmid were treated with ionomycin or DMSO
for 5 min. Cell extracts were then immunoblotted
for p-Thr172 AMPKa and total AMPKa.
(C) CaMKK2 forms a physical complex with AMPK,
ACC, and CaM. FLAG-CaMKK2 was immunopre-
cipitated from HEK293A cells transfected with
either FLAG-CaMKK2 or with control plasmid,
and the precipitates were immunoblotted for
p-Thr172 AMPKa, p-Ser79 ACC, CaM, or
CaMKK2. The presence of EDTA/EGTA during
cell lysis and immunoprecipitation blocked forma-
tion of the complex.
(D) AMPKa1 and a2 physically associate with
FLAG-CaMKK2. FLAG-CaMKK2 was immuno-
precipitated with or without EGTA/EDTA from
HEK293A cells that had been transfected with
either FLAG-CaMKK2 or control plasmid. The pre-
cipitates were immunoblotted for the AMPKa1 and
a2 subunits.
(E and F) The g subunit of AMPK is not detected in
the FLAG-CaMKK2/AMPK complex.
(E) HEK293A cell extracts or immunoprecipitated
FLAG-CaMKK2 was immunoblotted for AMPKa1,
b1/2, and g1 subunits.
(F) FLAG-CaMKK2 immunoprecipitated from
HEK293A cells and varying quantities of AMPK
heterotrimer overexpressed and purified from
bacteria were immunoblotted for AMPKa1, b1/2,
and g1 subunits.
(G) Deletion of the RP domain of CaMKK2 abol-
ishes interaction with AMPK. FLAG-CaMKK2 WT
(W) and RP deletion mutant (R) were immunopre-
cipitated from transfected HEK293A cells in the
absence of EGTA/EDTA and immunoblotted for
p-Thr172 AMPKa and total AMPKa. The bottom
panel shows Coomassie staining of the CaMKK2
proteins.
(H) FLAG-CaMKK2 WT and RP deletion mutant
were immunoprecipitated from transfected
HEK293A cells as described in (F) and immunoblotted for CaMKIV (upper panel) or Coomassie stained (lower panel).
(I) The CaMKK2 RP deletion mutant is able to activate a fragment of AMPKa in vitro. Recombinant AMPKa 1–312 served as substrate for purified CaMKK2 WT and
RP deletion mutant protein. Readout was 32P-labeled phosphate transferred to SAMS peptide by activated AMPK. Data are presented as means ± SEM. n =3.Cell Metabolism 7, 377–388, May 2008 ª2008 Elsevier Inc. 383
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CaMKK2 Regulates Energy Balanceassay (Figure 5G), although the ability of the mutant to coimmu-
noprecipitate CaMKIV, another CaMKK2 substrate, remained
unaltered (Figure 5H). When tested in vitro, the purified CaMKK2
RP deletion mutant could activate a fragment of the AMPK
catalytic subunit (AMPK 1–312) similarly to WT CaMKK2 in the
presence of saturating levels of Ca2+/CaM and MgATP and
a substrate excess of AMPKa 1–312 (Figure 5I). This not only
demonstrates that removal of the RP domain does not abrogate
the protein kinase activity of CaMKK2 but also suggests that
stable complex formation between CaMKK2 and AMPK is not
necessarily required for kinase-substrate interaction and may
thus provide some other role in vivo.
DISCUSSION
Recent obesity and type 2 diabetes research suggests that some
defects responsible for these conditions are due to altered re-
sponsiveness of key hypothalamic neurons to multiple metabolic
cues such as leptin, ghrelin, insulin, glucose, and fatty acids. As
a consequence, outputs emanating from these sites that are crit-
ical in regulating energy homeostasis become dysregulated. We
provide evidence here that hypothalamic CaMKK2 mediates
ghrelin-induced feeding. In the absence of CaMKK2, mice ate
less and accumulated less body weight and fat stores when
maintained on either low-fat or high-fat chow. The CaMKK2
null animals expressed reduced levels of hypothalamic NPY
and AgRP mRNAs and were unresponsive to the orexigenic
effects of exogenously administered ghrelin. Furthermore, i.c.v.
infusion of the selective CaMKK inhibitor STO-609 in adult WT
mice resulted in the acute suppression of NPY expression and
food intake. The resistance of CaMKK2 null mice to suppression
of food intake by STO-609 infusion provides compelling evi-
dence that CaMKK2 is the direct target of the drug and that
the specific inhibition of CaMKK2 in NPY neurons is likely
responsible for the decreased level of NPY and AgRP mRNAs
and feeding behavior.
Genetic and pharmacological data have demonstrated that
NPY and AgRP, as well as the NPY neurons in the ARC of the
hypothalamus where these neuropeptides are expressed, are
key intermediaries in the ghrelin-induced feeding response
(Cummings et al., 2005; Holst et al., 2005; Kojima et al., 1999;
Kushi et al., 1998; Sun et al., 2004). Binding of ghrelin to Gq-cou-
pled GHS-Rs expressed on NPY neurons leads to an increase in
intracellular Ca2+ and the phosphorylation/activation of AMPK,
each considered necessary for subsequent NPY gene induction
(Andersson et al., 2004; Holst et al., 2005; Kohno et al., 2003;
Kola et al., 2005). We hypothesize that CaMKK2 stimulates
NPY expression by functioning as the AMPKK linking ghrelin-
dependent Ca2+ signaling to AMPK activation. That theCaMKK2
null mice described in this study exhibited reduced hypothalamic
AMPK activity supports such a model.
We also present biochemical evidence for a CaMKK2-AMPK
signaling complex. The two kinases associate in a complex
also containing CaM, required for CaMKK2 activity, and ACC,
a downstream target of AMPK. The AMPK and ACC present in
the complex are phosphorylated on the appropriate residues,
Thr172 and Ser79 respectively, demonstrated by others to be
necessary for NPY gene induction in the hypothalamus and
appetite stimulation (Hu et al., 2005). Our data suggest a model384 Cell Metabolism 7, 377–388, May 2008 ª2008 Elsevier Inc.in which CaMKK2 interacts with the AMPKa subunit by substitut-
ing for the AMPKg subunit through a mechanism requiring the
RP domain of CaMKK2. The AMPKa subunit is unstable unless
bound to the regulatory bg heterodimer, as deletion of either
b or g markedly decreases the in vivo level of AMPKa (Crute
et al., 1998; Dyck et al., 1996). Our data suggest that CaMKK2
association with the AMPKa/b heterodimer provides an alternate
means of stabilizing AMPK, confers Ca2+ sensitivity and AMP
independence to the kinase, and is therefore fundamentally
different from the AMP-dependent LKB1-AMPK complex.
The hypothesis that CaMKK2 controls appetite by regulating
NPY signaling in the hypothalamus predicts that CaMKK2 and
NPY null mice will share the same metabolic phenotype. That
reduced refeeding after a fast is a behavior characteristic of
NPY depletion in mice that is phenocopied in CaMKK2 null ani-
mals (Figure 3A) supports this hypothesis. On the other hand,
NPY/NPY-Y null mice display a surprising lack of additional, pre-
dicted metabolic phenotypes. For example, when fed ad libitum,
these animals have normal appetite, normal or increased body
weight, increased adiposity, and increased serum leptin (Erick-
son et al., 1996; Kushi et al., 1998; Mashiko et al., 2003; Pedraz-
zini et al., 1998; Segal-Lieberman et al., 2003). This discrepancy
has been suggested to result from compensatory mechanisms
that rewire brain circuits during development (Kalra and Kalra,
2004). Similarly, we found that despite diminished NPY levels,
CaMKK2 null mice also showed normal appetite, slightly in-
creased body weight, increased adiposity, and increased levels
of circulating leptin and in these ways closely matched NPY/
NPY-Y null mice (see Figure S1 available online), but only while
fed Purina 5001 chow on which their parents were bred and
raised. Once CaMKK2 null mice were switched to the Surwit
diet, they began to eat less and accumulated less body weight
and fat on either low-fat or high-fat chow. Our data suggest
that, like NPY null animals, CaMKK2 null mice develop pathways
to compensate for diminished NPY signaling, and these path-
ways function to prevent eating disorders as long as the animals
are fed Purina 5001 chow. Once on the low- or high-fat Surwit
diets, the compensatory pathways acquired by CaMKK2 null
mice are apparently no longer effective, and the feeding defects
predicted from low NPY are exposed.
An intriguing phenotypic consequence of depleting CaMKK2
was observed in animals maintained on the high-fat diet, as
these mice were protected from the hyperglycemia and insulin
resistance that developed in WT controls over the course of
several months. Although the mechanism responsible for the
improved glucose handling is unknown, there are several possi-
bilities. Since obesity represents the leading risk factor for the
development of hyperglycemia (and type 2 diabetes), the im-
provements observed in CaMKK2 null mice may result directly
from them accumulating less body weight and fat stores com-
pared to WT mice prior to glucose and insulin testing (Golay
and Ybarra, 2005). Improved glucose tolerance is also consistent
with enhanced leptin signaling (Elmquist et al., 2005), implicated
in CaMKK2 null mice by decreased hypothalamic AMPK activity
(Minokoshi et al., 2004). In fact, it is possible that enhanced leptin
signaling in CaMKK2 null mice may contribute as well to the
observed decreases in food intake and body weight gain.
One major factor contributing to the onset of obesity in mam-
mals is the leptin resistance that develops as leptin levels rise in
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the level of the blood-brain barrier leptin transporter and/or
Socs3-negative feedback regulation of leptin receptor signaling
(Banks, 2003; Munzberg and Myers, 2005). If, as we hypothe-
size, CaMKK2 directly regulates hypothalamic AMPK activity,
then CaMKK2 null mice may enjoy enhanced leptin signaling
unaffected by the typical changes that bring about leptin resis-
tance. The recently reported haploinsufficient Socs3 mouse is
another example where the suppression of leptin sensitivity by
high-fat diet can be overcome by genetically altering hypotha-
lamic leptin signaling, in this case through a decrease in the
Socs3-mediated negative feedback regulation of the leptin re-
ceptor (Mori et al., 2004). High-fat diet-induced leptin resistance
can also be bypassed in mice by the pharmacological adminis-
tration of CNTF, which activates leptin signaling through a mech-
anism involving a decrease in hypothalamic AMPK activity
(Steinberg et al., 2006). Indeed, perhaps the central CaMKK2/
AMPK signaling axis is necessary for the development of insulin
resistance, which would contrast markedly with activation of
AMPK in peripheral tissues, as this is associated with increased
insulin sensitivity.
We also cannot rule out the possibility that CaMKK2 regulates
glucose homeostasis through direct action in the periphery. Islet
cells in the pancreas are known to express GHS-R and to respond
to ghrelin by blocking insulin secretion, which promotes hypergly-
cemia (Cummings et al., 2005). To our knowledge, the expression
of CaMKK2 in islet cells has not been evaluated, but, if present,
the kinase might mediate the response to ghrelin as we hypothe-
size occurs in the hypothalamus. GHS-R antagonists have been
shown to promote glucose tolerance in mice through action on
islet cells while at the same time suppressing appetite and pro-
moting weight loss through action in the hypothalamus (Esler
et al., 2007). Collectively, in mice these antagonists produce all
of the phenotypes observed by depleting CaMKK2.
In any event, the behavior of CaMKK2 null mice on the high-fat
diet underscores the value of targeting CaMKK2 as a possible
therapeutic locus in the treatment of obesity and diabetes. Inhi-
bition of CaMKK2 should selectively prevent AMPK activation in
the ARC, where doing so should produce the desirable effects of
reducing NPY gene induction and appetite. However, in periph-
eral metabolic tissues such as liver, muscle, and fat where abun-
dant evidence indicates that activation, not inhibition, of AMPK is
desirable for controlling obesity and diabetes (Hardie et al.,
2003), CaMKK inhibitors are unlikely to have direct effects for
at least two reasons. First, CaMKK protein expression in these
tissues is absent or very low (Anderson et al., 1998). Second,
LKB1 has been shown to function as the important AMPKK in
these contexts (Sakamoto et al., 2005; Shaw et al., 2005). Finally,
that depletion of CaMKK2 improves glucose tolerance while
suppressing appetite and promoting weight loss is a somewhat
unusual and quite desirable combination, as most current treat-
ments for type 2 diabetes promote weight gain—in turn a major
risk factor for the disease.
EXPERIMENTAL PROCEDURES
Animal Care
All animals were bred and maintained in either the Duke University Levine
Science Research Center or Vivarium animal facilities under a 12 hr light(0600–1800)/12 hr dark (1800–0600) cycle. Food and water were provided
ad libitum, and all animal care was in compliance within National Institutes
of Health and institutional guidelines on the care and use of laboratory and
experimental animals.
Targeted Deletion of the Mouse CaMKK2 Locus
The CaMKK2 gene was targeted by homologous recombination in embryonic
stem (ES) cells using the triple-lox/CaMKK2 targeting construct generated
from fragments of the CaMKK2 gene from the mouse 129/SvJ strain genomic
BAC library (Duke Genome Facility) and the triple-lox vector series created by
R.T. Premont (Gainetdinov et al., 1999). The targeting construct introduced
two loxP sites into the gene flanking exons 2–4, which encode elements of
the CaMKK2 ATP binding domain, as well as the neo cassette, also flanked
by loxP sites. A 7 kb HindIII fragment containing exon 1 (long recombination
arm) and the 4 kb HindIII-SbfI fragment containing exons 2–4 (the gene frag-
ment to be flanked by loxP sites) were ligated into the loxL vector. A 0.5 kb
AscI-HindIII fragment (short recombination arm) was ligated into the loxC/
diphtheria toxin vector. The appropriate restriction enzyme digests and ligation
steps were performed to generate the final targeting construct containing the
long recombination arm, floxed exons 2–4, the neo cassette, the short recom-
bination arm, and the diphtheria toxin cassette (Gainetdinov et al., 1999). After
identification of targeted ES cell clones by Southern analysis, the cells were
transiently transfected with Cre recombinase to delete CaMKK2 exons 2–4
and the neo cassette (confirmed by PCR analysis). Germline chimeras,
generated by blastocyst injections, were crossed with C57BL/6 mice, and
homozygous mutants and WT littermates were obtained from breeding of het-
erozygotes. Offspring were genotyped by PCR using forward primer 799–822,
50-TCAGTCAGTCTCACAGTGCCAAGC-30, and reverse primer 1992–1974, 50-
TTGAACTCCTGACCTTCGG-30, which produces an 900 bp band when
exons 2–4 have been deleted and no specific band from the WT locus. Forward
primer 257–278, 50-CGTCTTTCTTTTTTTGGGGGTG-30, and reverse primer
494–471, 50-CCTTGTTTGGGGAATGTGGAATAG-30, produce a 237 bp band
from exon 2, thus detecting the WT locus. The WT and CaMKK2 null mice
used in the experiments reported herein were backcrossed three generations
onto the C57BL/6J genetic background. The results presented in Figure 4 for
WT male mice are very similar to those previously reported for isogenic C57BL/
6J male mice (Surwit et al., 1988).
In Situ Hybridization
Brains were removed from 3-month-old mice, frozen in powdered dry ice, and
stored at 80C. Ten micrometer coronal sections, cut serially on a cryostat,
were collected at the midregion of the hypothalamus (bregma 1.7), thaw
mounted, and stored at 80C until use. The slides were then processed for
in situ hybridization by transferring directly into ice-cold 4% paraformaldehyde
and fixing for 10 min at room temperature. After a 10 min wash in 23 SSC,
sections were crosslinked for 5 min with an ultraviolet light placed 30 cm
from the tissue. Prehybridization, hybridization, and washing steps were
then performed as described previously (Anderson et al., 1998). RNA probes
were synthesized as follows: cDNAs encoding PCR-generated fragments of
NPY, MCH, and CaMKK2 coding regions were subcloned into the polylinker
of the pCR2 (Invitrogen) vector. The PCR primer pairs were forward primer
131–151 and reverse primer 665–646 for CaMKK2, 50-CTCCGCTCTGCGAC
ACCTAC-30 (forward) and 50-AATCAGTGTCTCAGGGCT-30 (reverse) for
NPY, and 50-ATTCAAAGAACACAGGCTCCAAAC-30 (forward) and 50-CGGA
TCCTTTCAGAGCGAG-30 (reverse) for MCH. Runoff [S35]UTP-labeled sense
and antisense transcripts corresponding to base pairs 10–524 of CaMKK2,
base pairs 220–294 of NPY, and base pairs 307–399 of MCH were generated
using SP6 or T7 RNA polymerase according to the manufacturer’s protocol
(Promega). Unincorporated nucleotides were removed by washing the
EtOH-precipitated RNA pellets with 70% EtOH.
Hypothalamic mRNA Quantification
Total RNA from hypothalamus was extracted using an RNeasy Mini Kit
(QIAGEN) and quantified spectrophotometrically. Single-stranded cDNA was
synthesized using SuperScript III RNase H Reverse Transcriptase (Invitrogen)
according to the manufacturer’s directions. Real-time PCR was carried out
using an iCycler (Bio-Rad) with iQ SYBR Green Supermix (Bio-Rad) and
the following primers: AgRP, 50-GCGGAGGTGCTAGATCCA-30 (forward) andCell Metabolism 7, 377–388, May 2008 ª2008 Elsevier Inc. 385
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ACTAC-30 (forward) and 50-AATCAGTGTCTCAGGGCT-30 (reverse); POMC,
50-ACCTCACCACGGAGAGCA-30 (forward) and 50-GCGAGAGGTCGAGTTTG
C-30 (reverse); 18S ribosomal protein, 50-AGGGTTCGATTCCGGAGAGG-30
(forward) and 50-CAACTTTAATATACGCTATTGG-30 (reverse). After deriving
the relative amount of each transcript from a standard curve, NPY, AgRP,
and POMC transcript levels were normalized to 18S ribosomal RNA.
AMPK Immunoprecipitation and Activity
Mouse hypothalamus was homogenized in Triton lysis buffer containing
20 mM Tris-Cl (pH 7.4), 50 mM NaCl, 50 mM NaF, 5 mM NaPPi, 250 mM su-
crose, 1% Triton X-100, 1 mM DTT, 1 mg/ml leupeptin, 10 mg/ml pefabloc,
1 mg/ml aprotinin, and 100 nM okadaic acid. After pelleting the insoluble ma-
terial, AMPKa was immunoprecipitated from protein-matched extracts using
an antibody directed against residues 2–20 of the a subunit (Chen et al.,
2003) and assayed on beads for AMPK activity against the SAMS peptide as
described previously (Hurley et al., 2006).
Dual Energy X-Ray Absorptiometry
Mice were anesthetized (ketamine 100 mg/kg; xylazine 10 mg/kg) and
scanned four times (with no repositioning between scans) using a Lunar
PIXImus II densitometer (software version 2.0; GE Lunar Corp.). All mice
were granted ad libitum access to food and water before dual energy X-ray ab-
sorptiometry (DEXA) measurements, which were typically performed between
0800 and 1130. Calibration of the instrument was conducted as recommended
by the manufacturer. Briefly, an aluminum/Lucite phantom (total bone mineral
density = 0.0594 g/cm2, percentage fat = 12.4%) was placed on the specimen
tray and measured four times without repositioning. The phantom was mea-
sured daily before animal testing to ensure quality control. Anesthetized
mice were then placed on the imaging positioning tray in a prostrate fashion
with the front and back legs extended away from the body. Heads were
excluded from all analyses by placing an exclusion region of interest (ROI)
over the head. Thus, all body composition data exclude the head.
Serum Hormone Analysis
Mice with unrestricted access to food and water were collected at 0900 and
sacrificed by decapitation, and blood was collected from the trunk. Blood
samples were centrifuged at 14,000 rpm at 4C, and serum was flash frozen
in liquid N2. Radioimmunoassays (Linco Research) were used to quantify
leptin, adiponectin, ghrelin, glycerol, and free fatty acids.
Glucose and Insulin Tolerance Assays
Glucose tolerance assays were performed on mice that were fasted overnight
(>12 hr). At 0900, mice were measured for baseline glucose by collecting
a small drop of blood from the tail vein for analysis using a handheld Bayer
Ascensia Contour glucometer. After the baseline glucose values were estab-
lished, each mouse was given an i.p. injection of 2 mg glucose/g body weight.
Blood glucose was quantified as a function of time until glucose levels returned
to near baseline values. Insulin tolerance was conducted using the same gluc-
ometer, also at 0900. Mice were fasted for 3 hr prior to starting the procedure.
After the baseline glucose values were established, mice were given recombi-
nant human insulin (1 U/kg i.p. Eli Lilly). Clearance of plasma glucose was
subsequently monitored at 15, 30, and 60 min postinjection.
Cannulation and Infusion of STO-609
Insertion of cannulae (Plastics One) and subsequent infusion of solutions into
the third ventricle of adult WT or CaMKK2 null mice using Alzet osmotic mini-
pumps (DURECT Corporation) were performed as follows. A stock solution of
STO-609 (20 mM in 100 mM NaOH) was diluted 1:1000 in 0.9% sterile saline to
obtain a 20 mM working concentration in 100 mM NaOH (pH  7.0). One hun-
dred microliters of STO-609 or carrier was loaded into individual osmotic mini-
pumps (Alzet model 1007D) 12 hr prior to surgical implantation and allowed to
equilibrate in 0.9% sterile saline at 37C to ensure that the pumps began to
work immediately after implantation at the maximal flow rate of 0.5 ml/hr. Prior
to surgery, mice were administered ketamine 80 mg/kg; xylazine 10 mg/kg i.p.
After the anesthetic had taken effect, mice were secured in a stereotaxic
apparatus (Kopf Instruments), and an incision was made down the midline of
the head to expose the skull. After swabbing the exposed skull with 95%386 Cell Metabolism 7, 377–388, May 2008 ª2008 Elsevier Inc.EtOH to remove any contaminants, the bregma line was located and marked.
A small access hole was drilled at bregma1.94, and the cannula was inserted
to a depth of 5.8 mm and secured with epoxy bone cement. After the bone
cement dried, a small incision was made in the skin between the scapulae.
A small pocket was formed in the subcutaneous tissue, and the pump was
implanted and connected to the cannula via a small sterile plastic tube. The
incision was then closed, and the animal was placed on a heating pad to
recover. Mice were monitored daily for normal behavior over a 7 day period,
at which time they were sacrificed, and the hypothalamus was removed for
RNA extraction.
Immunoblotting
Samples were fractionated by SDS-PAGE and transferred to Immobilon-P
membranes (Millipore). All blocking and secondary antibody incubation steps
were performed in TBS containing 5% nonfat milk, while primary antibody
incubations were performed in TBS containing 5% BSA. Washes were per-
formed in TBS with 0.5% Tween 20. AMPKa anti-phospho-Thr172, anti-
AMPKa, anti-AMPKa1, anti-AMPKa2, and ACC anti-phospho-Ser79 were
used at 1:1000 dilution. Anti-AMPKb1/2 (Epitomics, Inc., #1604-1) was used
at 1:5000, and anti-AMPKg1 (Epitomics, Inc., #1592-1) was used at 1:1000.
Anti-CaMKK2 (Santa Cruz L-19, #sc-9629) was used at 1:200, anti-CaMKIV
(BD Biosciences, #610276) was used at 1:2000, and anti-CaM (Upstate
Biotechnology, #05-173) was used at 1:1000. Horseradish peroxidase-conju-
gated secondary antibodies were from Jackson ImmunoResearch Laborato-
ries, Inc., and were used at 1:5000 with an ECL kit from Amersham Biosciences.
Cells, Cell Culture, Cell Transfection, and Cell Stimulation
The human embryonic kidney cell line QBI-293A (HEK293A) from Quantum
Biotechnologies was cultured as recommended by the supplier. The immortal-
ized mouse hypothalamic cell line N38 from CELLutions Biosystems was cul-
tured as recommended by the supplier, except that charcoal-stripped FBS
was used in the growth medium. Cells were transfected with pSG5-FLAG-
CaMKK2 or empty pSG5 vector (Stratagene) using Lipofectamine 2000
reagent (Invitrogen) according to the manufacturer’s recommendations and
cultured 16–24 hr before stimulation with ionomycin. Extracts of HEK293A or
N38 cells were prepared by scraping the cells in NP-40 lysis buffer containing
25 mM Tris-HCl (pH 7.4), 50 mM NaCl, 0.5% NP-40, 25 mM NaH2PO4, 2 mM
EGTA, 2 mM EDTA, 50 mM NaF, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 10 mg/ml
pefabloc, and 100 nM okadaic acid. After 30 min on ice, insoluble material was
pelleted by centrifugation at 14,000 3 g for 20 min, and the supernatant was
reserved for immunoblot analysis.
Immunocytochemistry to Detect NPY Protein in N38 Cells
N38 cells were cultured on glass coverslips. Following treatment with STO-
609, ionomycin, or 2-DG, the cells were fixed for 10 min in 1% paraformalde-
hyde/PBS and washed and permeabilized for 10 min in 0.05% Triton X, 20 mM
Tris (pH 7.4), 50 mM NaCl, 300 mM sucrose, and 3 mM MgCl2. After permea-
bilization, the cells were washed and blocked for 20 min in 5% normal sheep
serum/PBS and incubated overnight at 4C with rabbit anti-NPY (Sigma,
N9528) diluted 1:4000 in 5% sheep serum/PBS. The cells were washed and
incubated in the dark for 1 hr with anti-rabbit Cy3 (Jackson ImmunoResearch
Laboratories, Inc.) diluted 1:200 in 5% sheep serum/PBS, washed again, and
mounted in hard-set mounting medium (Vectashield) with DAPI. All washing
steps were performed in triplicate for 5 min with PBS, and the procedure
was performed at room temperature except for the 4C incubation with
primary antibody.
CaMKK2-AMPK Coimmunoprecipitation
and AMPK Heterotrimer Purification
Unstimulated transfected cells were harvested in NP-40 lysis buffer as
described above with or without EDTA/EGTA as indicated, and the resulting
supernatant was incubated for 2 hr at 4C with 20 ml anti-FLAG M2 agarose
(Sigma, A2220). The resin was washed 23 with NP-40 lysis buffer and 13
with TBS prior to elution of the FLAG-CaMKK2 protein in 40 ml TBS containing
300 ng/ml FLAG peptide (Sigma, F3290). The eluted protein was then analyzed
by immunoblot. Recombinant trimeric AMPK was expressed and purified from
bacteria as described previously (Neumann et al., 2003).
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The CaMKK2 RP deletion mutant was generated using the QuikChange
Site-Directed Mutagenesis Kit (Stratagene) with rat CaMKK2 WT cDNA as
template and the primers 50-CCAAAAAGAAGCTGATCCGAAGGGGCCCC
ATCGAGCAGG-30 (sense) and 50-CCTGCTCGATGGGGCCCCTTCGGATCAG
CTTCTTTTTGG-30 (antisense). The nucleotide sequence of the entire cDNA
was confirmed by automated sequencing (Duke University DNA Sequencing
Facility).
In Vitro CaMKK2 Activity
FLAG-CaMKK2 WT and RP deletion mutant were expressed in HEK293A cells,
immunoprecipitated, and eluted from FLAG resin as described above. After
assessing protein purity and quantity by fractionating aliquots by SDS-PAGE
along with g-globulin standards and quantification of Coomassie-stained
bands, activity was measured by adding FLAG-CaMKK2 to the reaction at
a concentration of 4 nM, along with the substrate MBP-AMPKa 1–312 at
200 nM. When measuring Ca2+/CaM-dependent activity, the reaction also
contained 25 mM HEPES (pH 7.5), 0.1% Tween 20, 10 mM MgCl2, 400 mM
ATP, 1 mM CaM, 1 mM CaCl2, 20 mM SAMS peptide, and 0.024 mCi/ml
[g-32P]ATP. Ca2+/CaM-independent activity was determined by including
2 mM EGTA in the reaction described above. Readout was the transfer of
32P to SAMS peptide by activated AMPK, which was quantified by a phospho-
cellulose method as described previously (Anderson et al., 1998).
SUPPLEMENTAL DATA
Supplemental Data include one table and one figure and can be found with this
article online at http://www.cellmetabolism.org/cgi/content/full/7/5/377/DC1/.
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